LAPTM4BP2

Across TCGA pan-cancer cohorts, LAPTM4BP2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of LAPTM4BP2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LAPTM4BP2 RNA is repressed in tumor relative to normal tissue. In most cancer types LAPTM4BP2 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

KIRC, COAD, and UCEC are the cancer types where LAPTM4BP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LAPTM4BP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	−0.047	<.001	8	view →
COAD	All	All	+0.158	.017	5	view →
UCEC	All	II,III,IV	+0.671	.027	4	view →
BRCA	All	II,III,IV	+0.061	<.001	4	view →
LUSC	All	II,III,IV	+0.063	.027	3	view →
LUAD	All	All	+0.121	.004	2	view →
LIHC	Male	All	+0.020	.039	2	view →
HNSC	All	All	+0.027	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

LAPTM4BP2–KIRC

Open the KIRC breakdown →